NRL001 not checked
Norgine · methoxamine gel 0.3% · 1.0%
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single application of 0.3%, 1.0%, 3.0% NRL001 gel in stepwise dose ascending fashion.”In the company’s words, NCT06593743 on ClinicalTrials.gov
- Tested for
- Faecal Incontinence (2 trials)
- Main trialPhase 1
- “Single centre dose-finding and proof-of-concept study in healthy volunteers to assess the effects of single doses of NRL001 on the mean anal resting pressure (MARP). In addition, the pharmacokinetics of NRL001 and subject safety are also examined.”In the company’s words, NCT06593743 on ClinicalTrials.gov
- Other names
- methoxamine gel 0.3% · 1.0% · 3.0% · methoxamine gel 3.0% · methoxamine gel 1.0% · methoxamine suppository
Other drugs for Faecal Incontinence
- IltamiocelCook MyoSite · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | Jul 2004 | The Safety and Dose Response to Single Anal Doses of NRL001 | |
| Phase 1Completed | Aug 2007 | Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026